ASCO 2021: Prostate Cancer ASCO 2021: Bladder Cancer and RCC Urology Times Journal Urologists in Cancer Care UroView Around the Practice

ASCO 2021: Prostate CancerASCO 2021: Bladder Cancer and RCCUrology Times JournalUrologists in Cancer CareUroViewAround the Practice

Clinical

View More Prostate Cancer Bladder Cancer Kidney Cancer BPH OAB and Incontinence Kidney Stones Sexual Dysfunction Hormone Therapy Next-Generation Imaging

Prostate CancerBladder CancerKidney CancerBPHOAB and IncontinenceKidney StonesSexual DysfunctionHormone TherapyNext-Generation Imaging

Business

View More Health Law & Policy Malpractice Consult Practice Management

Health Law & PolicyMalpractice ConsultPractice Management

News

Clinical

All Clinical Benign Conditions Bladder Cancer BPH Female Urology Genitourinary Cancers Hormone Therapy Kidney Cancer Kidney Stones Men's Health Next-Generation Imaging Pediatrics Prostate Cancer Sexual Dysfunction Urologic Surgery

All ClinicalBenign ConditionsBladder CancerBPHFemale UrologyGenitourinary CancersHormone TherapyKidney CancerKidney StonesMen's HealthNext-Generation ImagingPediatricsProstate CancerSexual DysfunctionUrologic Surgery

Media

Podcasts 'Y'tube UroView UTv Videos Around the Practice BPH Videos Medical World News Readout 360 Viewpoints

Podcasts'Y'tubeUroViewUTv VideosAround the PracticeBPH VideosMedical World NewsReadout 360Viewpoints

Conferences

Publications

Supplements and Featured Publications Urologists in Cancer Care Urology Times Journal

Supplements and Featured PublicationsUrologists in Cancer CareUrology Times Journal

Events

Live Events Virtual Events

Live EventsVirtual Events

CME/CE

Resources

Interactive Tools Job Board Partners Sponsored

Interactive ToolsJob BoardPartnersSponsored

eNewsletter Print Subscription

eNewsletterPrint Subscription

About Us
Advertise
Contact Us
Job Board
Terms and Conditions
Privacy
Do not sell my Personnal Information

Spotlight

ASCO 2021: Prostate Cancer
ASCO 2021: Bladder Cancer and RCC
Urology Times Journal
Urologists in Cancer Care
UroView
Around the Practice

ClinicalSee All >

Prostate Cancer
Bladder Cancer
Kidney Cancer
BPH
OAB and Incontinence
Kidney Stones
Sexual Dysfunction
Hormone Therapy
Next-Generation Imaging

BusinessSee All >

Health Law & Policy
Malpractice Consult
Practice Management

About Us
Advertise
Contact Us
Job Board
Terms and Conditions
Privacy
Do not sell my Personnal Information

Formulation decreases risk of recurrent stone formation

May 12, 2004

Orthophosphate formula (Uro-KP-Neutral) from Star Pharmaceuticals decreasesthe risk of recurrent calcium oxalate stone formation and the growth ofresidual stones following lithotripsy. In addition, the formulation is agood source of supplemental potassium, sodium, and phosphorus, accordingto the company.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria